The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
Open accessAbstract
Obesity, insulin resistance (IR), and the gut microbiome intricately interplay in Metabolic-associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty Liver Disease (NAFLD), a growing health concern. The complex progression of MASLD extends beyond the liver, driven by "gut-liver axis," where diet, genetics, and gut-liver interactions influence disease development. The pathophysiology of MASLD involves excessive liver fat accumulation, hepatocyte dysfunction, inflammation, and fibrosis, with subsequent risk of hepatocellular carcinoma (HCC). The gut, a tripartite barrier, with mechanical, immune, and microbial components, engages in a constant communication with the liver. Recent evidence links dysbiosis and disrupted barriers to systemic inflammation and disease progression. Toll-like receptors (TLRs) mediate immunological crosstalk between the gut and liver, recognizing microbial structures and triggering immune responses. The "multiple hit model" of MASLD development involves factors like fat accumulation, insulin resistance, gut dysbiosis, and genetics/environmental elements disrupting the gut-liver axis, leading to impaired intestinal barrier function and increased gut permeability. Clinical management strategies encompass dietary interventions, physical exercise, pharmacotherapy targeting bile acid (BA) metabolism, and microbiome modulation approaches through prebiotics, probiotics, symbiotics, and fecal microbiota transplantation (FMT). This review underscores the complex interactions between diet, metabolism, microbiome, and their impact on MASLD pathophysiology and therapeutic prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MASLD is a progressively worsening liver condition characterized by pathological processes including fat accumulation, cell death, inflammation, and fibrosis within liver cells [68–70].”
From Constructing biomimetic microenvironments for liver regeneration (2025) · doi:10.1186/s12951-025-03729-9 · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Role of the gut microbiome in chronic diseases: a narrative review
Vijay, A., & Valdes, A. M. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00991-6 · Cited by 361 · cited 1×
“66,67”
RetractedHuman gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 1×
“119,120 Other studies show that obese profiles might also exhibit low levels of SCFAs.”
BackgroundHuman gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815 · cited 2×
“53 Human adult microbiota is composed of 100 trillion microorganisms that include commensal bacteria, pro-and anti-inflammatory, pathogenic, and nonpathogenic bacteria, fungi, and viruses that maintain gut homeostasis.”
BackgroundChanges of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638 · cited 1×
“113,137 Dietary fiber plays a crucial role in creating an optimal gut environment that supports the flour-ishing of beneficial bacteria (eubiosis), resulting in beneficial physiological effects such as reduced plasma cholesterol and glucose levels.”
BackgroundLinking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513 · cited 1×
“136 Balanced and healthy diet enhances the integrity of the gut barrier, increases mucus production, lowers luminal pH, and reduces the leakage of microbes into the bloodstream.”
BackgroundThe gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 2×
“120 Therefore, the gut microbiota environment together with a specific diet can have an impact on host metabolism.”
BackgroundRevised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“54,55 The intestinal microbiota increases in density from the small intestine to the colon, where it reaches approximately 10 trillion cells per gram of colonic content.”
BackgroundGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Cited by
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 162
“The interplay between microbial signals and hepatic immune responses represents a critical component in the pathogenesis of HCC, particularly in the context of chronic liver injury and metabolic liver diseases [9, 64 – 66].”
NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options
Vallianou, N. G., Kounatidis, D. C., Psallida, S., Vythoulkas-Biotis, N., Adamou, A., Zachariadou, T., Kargioti, S., Karampela, Ι., & Dalamaga, Μ. (2024) · Metabolites · doi:10.3390/metabo14070366 · Cited by 110
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
“The complicated progression of MASLD extends beyond the liver, driven by the “ gut ‒ liver axis ” , where diet and genetic and gut ‒ liver interactions affect disease outcomes [164].”
Cui, C., Gao, S., Shi, J., & Wang, K. (2025) · Gut and Liver · doi:10.5009/gnl240539 · Cited by 80
“48 Notably, the activation of NLRP3 inflam-masomes in MASLD triggers the production of inflammatory cytokines IL-1 β and IL-18, further exacerbating the inflammatory response.”
Hawley, J. A., Forster, S. C., & Giles, E. M. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.01.224 · Cited by 81
Metadata
- Authors
- Benedé-Ubieto, R., Cubero, F. J., & Nevzorova, Y. A.
- Affiliations
- Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Nevzorova, Yulia A.
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2024-03-21
- Volume
- 16
- Issue
- 1
- Pages
- 2331460-2331460
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- PMC
- PMC10962615
- OpenAlex
- W4393033456
- Cited by
- 242
- References
- 185
- Citations by year
- 2026: 106 · 2025: 106 · 2024: 30
- FWCI
- 15.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Gut Microbes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- MICINN (PID2020-117827RB-IOO/AEI/10.13039/501100011033)
- Comunidad de Madrid
- Universidad Complutense de Madrid (CT63/19)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- non-alcoholic fatty liver disease, gut-liver axis, gut dysbiosis, intestinal barrier function, intestinal permeability, insulin resistance, obesity, Toll-like receptors, liver inflammation, liver fibrosis, hepatocellular carcinoma, bile acid metabolism, prebiotics, probiotics, fecal microbiota transplantation, microbiota modulation, dietary intervention, physical activity
- MeSH terms
- Gastrointestinal Microbiome, Carcinoma, Hepatocellular, Homeostasis, Humans, Inflammation, Insulin Resistance, Liver Neoplasms, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). https://app.cochat.ai/papers/10.1080/19490976.2024.2331460
- The paper
- Benedé-Ubieto, R., Cubero, F. J., & Nevzorova, Y. A. (2024). Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. https://doi.org/10.1080/19490976.2024.2331460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.